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Background: The aim of our study was to investigate the incidence of papillary thyroid microcarcinoma (PTMC) in
patients operated for benign thyroid diseases (BTD) and its relation to age, sex, extent of surgery and type of BTD.
Methods: Retrospective study of 2466 patients who underwent thyroid surgery for BTD from 2008 to 2013. To
determine independent predictors for PTMC we used three separate multivariate logistic regression models (MLR).
Results: There were 2128 (86.3%) females and 338 (13.7%) males. PTMC was diagnosed in 345 (16.2%) females and
58 (17.2%) males. Age ranged from 14 to 85 years (mean 54 years). Sex and age were not related to the incidence
of PTMC. The overall incidence of PTMC was 16.3%. The highest incidence was in Hashimoto thyroiditis (22.7%,
χ2 = 10.80, p < 0.001); and in patients with total/near-total thyroidectomy (17.7%, χ2 = 7.05, p < 0.008). The lowest
incidence (6.6%, χ2 = 9.96, p < 0.001) was in a solitary hyperfunctional thyroid nodule (SHTN). According to MLR,
Hashimoto thyroiditis (OR 1.54, 95% CI 1.15-2.05, p < 0.003) and SHTN (OR 0.43, 95% CI 0.21-0.87, p < 0.019) are
independent predictors. Since the extent of surgery was an independent predictor (OR 1.45, 95% CI 1.10-1.92,
p = 0.009) for all BTD, and sex and age were not; when the MLR model was adjusted for them, Graves disease
(OR 0.72, 95% CI 0.53-0.99, p < 0.041) also proved to be an independent predictor.
Conclusions: Sex and age are not statistically related to the incidence of PTMC in BTD. The incidence of PTMC is
higher in Hashimoto thyroiditis and patients with total/near-total thyroidectomy; and lower in patients with a SHTN
and Graves disease.
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Thyroid cancer (TC) is considered the most common
malignancy of the endocrine system, with an incidence
that ranges from 1 to 8 per 100,000 [1]. Over the past
few decades, TC incidence has dramatically increased,
and is considered, in some parts of the world, the se-
cond, and even the first most common cancer in women
[2,3]. This is even more intriguing when we take into ac-
count that the overall cancer incidence rates for other* Correspondence: dr.nikola.slijepcevic@gmail.com
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unless otherwise stated.localizations have mainly decreased for both women and
men [4]. This remarkable increase of TC incidence is
associated mainly with well-differentiated TC, above all
papillary thyroid cancer (PTC). PTC constitutes more
than 70% of TC [5]. This increase in the incidence of TC
is mainly recognized as an increased detection of papil-
lary thyroid microcarcinoma (PTMC) [6]. PTMC is
defined as tumours of less than or equal to 10mm in
diameter [7]. PTMC can be non-incidental or incidental.
Non-incidental PTMC is usually diagnosed on the basis of
fine-needle aspiration biopsy (FNAB), local or distant
metastasis. Incidental PTMC is most commonly disco-
vered on definitive paraffin section examination followingtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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has a different incidence rate compared to clinically
evident PTC. There is no universally accepted approach to
PTMC and treatment ranges from observation, hemithy-
roidectomy, total thyroidectomy and total thyroidectomy
with central lymph node dissection followed by radio-
active iodine treatment [8,9]. The aim of our study was to
investigate the incidence of PTMC in patients operated
for BTD, establish whether its incidence is related to age,
sex, extent of surgery and type of BTD and identify po-
tential independent positive and negative predictors of
PTMC.
Methods
A retrospective study was conducted at a high volume
specialized endocrine surgery unit of a tertiary referral
university hospital. The study was approved by the ethic
committee of the tertiary referral university hospital.
Data were gathered from the database of all consecutive
patients who underwent thyroid surgery for BTD in a
five-year period (May 2008 to May 2013). All of these
patients, during the process of making the diagnosis of
BTD, undergo a standard diagnostic workup which in-
cludes laboratory tests, ultrasound examinations, and in
selected cases scintigraphy, FNAB (fine needle aspiration
biopsy) and a chest X-ray. All patients with clearly palp-
able non-hyperfunctional thyroid nodules greater than
10mm and with a normal value of calcitonin, undergo
FNAB. We routinely test calcitonin in all of our patients
with thyroid nodules of any size, thus eliminating the
possibility of overlooking medullary thyroid cancer. We
usually do not perform FNAB for nodules of size less
than 10mm, since ultrasound guided FNAB is not rou-
tinely used in our healthcare setting.
All patients that underwent thyroid surgery for BTD,
with or without an incidentally discovered PTMC on
definitive paraffin section examination, were included
in the study. All our pathohistological examinations are
performed by three experienced endocrine pathologists
with more than 20 years of working experience in this
field. The protocol for pathohistological examination fol-
lows well established standards. A standard hematoxylin
and eosin staining protocol for examining surgical speci-
mens is used, whereas immunohistochemistry is used in
selected cases. If the diagnosis is uncertain, the final
diagnosis is based on the consensus of two pathologists.
Patients with non-incidental PTMC were excluded from
the study, as were all patients that had, apart from BTD,
a TC greater than 10mm. All patients that had medullary
TC or non-papillary TC of any size were also excluded
from the study. The studied group consisted of 2466 pa-
tients with BTD of which 403 patients had an inciden-
tally discovered PTMC on definitive paraffin section
examination. In the studied group of patients with BTD,the most common indications for surgery were hyperthy-
roidism, a solitary nodule and thyroid enlargement with
compressive symptoms (dysphagia, dyspnoea, hoarseness).
We analysed sex, age, type of BTD and extent of sur-
gery in relation to the incidence of PTMC. According to
type of BTD, patients were classified into the follo-
wing groups: patients with multinodular goitre (MNG),
Hashimoto thyroiditis, Graves’s disease, Plummer’s dis-
ease, solitary hyperfunctional thyroid nodule (SHTN)
and benign tumours (which included colloid adenoma,
follicular adenoma, Hurthle-cell adenoma and thyroid
cysts). Within the group of benign thyroid tumours we
did not find any statistical differences in relation to
PTMC. Thus we formed one group - benign tumours.
The extent of surgery was classified into two groups: HT
group – less than total thyroidectomy (Dunhill pro-
cedure, hemithyroidectomy with isthmectomy and other
less radical procedures) and TT group – total thyroidec-
tomy (near total or total thyroidectomy).
Regarding age, a ten-year age group interval was used
because of the small numbers that a five-year age group
would produce resulting in unstable rates. For the same
reason the age groups <20 and 70+ were formed. The
statistical relationship between incidence of PTMC and
sex, age, type of BTD and extent of surgery were first
tested with Pearson's Chi-Square test and Fisher's exact
test, with a two-sided value of p. To determine inde-
pendent predictors for PTMC we used three separate
multivariate logistic regression models (MLR). The first
model tested all variables and their relation to PTMC.
All variables that were statistically related to PTMC in
univariate logistic regression (ULR) at the level of signifi-
cance of p < 0.1, were included in the MRL model. In
the second model we tested all variables and their rela-
tion to the extent of surgery. Here, also, all variables that
were statistically related to the extent of surgery in ULR
at the level of significance of p < 0.1, were included in
the MRL model. Finally, in the third model we per-
formed MLR for each type of BTD in relation to PTMC
but adjusted for sex, age and extent of surgery. This
MLR model was adjusted for sex, age and extent of sur-
gery, since sex and age were not statistically significantly
related to PTMC; and extent of surgery was statistically
significantly related to PTMC and type of BTD for each
BTD, except for MNG. SPSS version 16.0.2 (SPSS Inc.,
Chicago, Illinois, USA) was used to perform the statis-
tical analysis.
Results
The incidence of PTMC in relation to sex, age group,
type of BTD and extent of surgery are presented in
Table 1. The overall incidence of PTMC in BTD was
16.3%. In our studied group of patients with BTD (2128
females and 338 males) women outnumbered men
Table 1 Incidence of PTMCa in relation to sex, age, BTDb and extent of surgery
All cases Cases with PTMC Cases without PTMC Pearson chi-square
N % N % N % Value p
Sex
Males 338 13.7 58 17.2 280 82.8
.191 .692
Females 2128 86.3 345 16.2 1783 83.8
Age
<20 29 1.2 4 13.8 25 86.2
3.920 .687
21-30 173 7.0 20 11.6 153 88.4
31-40 353 14.3 56 15.9 297 84.1
41-50 489 19.8 84 17.2 405 82.8
51-60 684 27.7 119 17.4 565 82.6
61-70 545 22.1 88 16.2 457 83.8
70+ 193 7.8 32 16.6 161 83.4
BTD
MNGc 1143 46.4 188 16.4 955 83.6 .017 .913
Hashimoto 317 12.9 72 22.7 245 77.3 10.799 .001
Graves 457 18.5 65 14.2 392 85.8 1.842 .183
Plummer's 278 11.3 38 13.7 240 86.3 1.638 .228
SHTNd 136 5.5 9 6.6 127 93.4 9.956 .001
Benign tumour 875 35.5 142 16.2 733 83.8 .013 .955
Extent of surgery
HT groupe 762 30.9 102 13.4 660 86.6
7.050 .008
TT groupf 1704 69.1 301 17.7 1403 82.3
Total 2466 100 403 16.3 2063 83.7 N/A
aPapillary thyroid microcarcinoma; bBenign thyroid disease; cMNG Multinodular goitre; dSHTN Solitary hyperfunctional thyroid nodule; eLess than total or near-total
thyroidectomy; fTotal or near-total thyroidectomy.
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PTMC (345 females and 58 males), a similar ratio was
noted (5.9:1). The incidence of PTMC in females (16.2%)
was slightly lower than in males (17.2%), but did not
prove to be statistically significant. The youngest patient
in our study was 14 years old and the oldest was 85
years old, with a mean age of 54 years. The youngest pa-
tient with PTMC was 15 years old and the oldest was 81
years old. The highest incidence of 17.4% was noted in
the age group 51-60. Age did not prove to be statistically
significantly related to the incidence of PTMC. Even
though 47% of all PTMC cases were in the MNG group
its incidence (16.4%) did not prove to be statistically
significant (χ2 = 0.02, p > 0.05). The highest incidence of
PTMC (22.7%) was noted in the group of patients with
Hashimoto thyroiditis, where there were 72 patients
with PTMC (18% of all PTMC cases), and it proved to
be highly statistically significant (χ2 = 10.80, p < 0.001).
The lowest incidence of PTMC (6.6%) was noted in the
group of patients with a SHTN where there were only 9
patients with PTMC (2% of all PTMC cases), and this also
proved to be highly statistically significant (χ2 = 9.96,p < 0.001). There were roughly three times more cases
with PTMC in the TT group than in the HT group. The
incidence of PTMC was higher in the TT group compared
to the HT group (17.7% vs. 13.4%), and was statistically
significant (χ2 = 7.05, p = 0.008). Table 2 shows the results
of the first MLR model we performed where we tested all
variables and their relation to PTMC. According to
ULR, Hashimoto thyroiditis (OR 1.61, 95% CI 1.21-2.15,
p < 0.001), SHTN (OR 0.35, 95% CI 0.18-0.69, p < 0.003)
and extent of surgery (OR 1.39, 95% CI 1.09-1.77, p < 0.008)
were statistically significantly associated with PTMC.
According to our first MLR model, we found that an
independent positive predictor of PTMC was Hashimoto
thyroiditis (OR 1.54, 95% CI 1.15-2.05, p < 0.003), while a
SHTN proved to be a independent negative predictor of
PTMC (OR 0.43, 95% CI 0.21-0.87, p < 0.019). Table 3
shows the results of the second MLR model we performed
where we tested all variables, including PTMC and their
relation to the extent of operation. According to ULR, the
extent of operation was statistically significantly associated
with all variables, except sex, age and MNG. The results
of this MLR showed that each type of BTD is highly
Table 2 Univariate and multivariate logistic regression of
sex, age, type of BTDa and extent of surgery in relation
to PTMCb
Variable ORc 95% CId pe
Univariate logistic regression analysis
Sex .934 .688-1.268 .662
Age 1.025 .965-1.088 .421
MNGf 1.015 .819-1.257 .895
Hashimoto 1.614 1.211-2.152 .001
Graves .820 .615-1.093 .175
Plummer's .791 .552-1.134 .202
SHTNg .348 .176-.691 .003
Benign tumour .987 .790-1.234 .987
Extent of surgery 1.388 1.089-1.770 .008
Multivariate logistic regression analysis (p < 0.10)
Hashimoto 1.539 1.153-2.054 .003
SHTN .428 .211-.868 .019
aBenign thyroid disease; bPapillary thyroid microcarcinoma; cOdds ratio;
dConfidence interval; eStatistical significance; fMultinodular goitre; gSolitary
hyperfunctional thyroid nodule.
Table 3 Univariate and multivariate logistic regression of
sex, age, type of BTDa and PTMCb in relation to extent
of operation
Variable ORc 95% CId pe
Univariate logistic regression analysis
Sex 1.255 .986-1.598 .065
Age 1.042 .933-1.093 .095
MNGf .986 .831-1.171 .874
Hashimoto 1.327 1.015-1.733 .038
Graves 15.255 9.319-24-972 .000
Plummer's 5.947 3.813-9.274 .000
SHTNg .033 .018-.062 .000
Benign tumour .119 .098-.144 .000
PTMC 1.388 1.089-1.770 .008
Multivariate logistic regression analysis (p < 0.1)
Hashimoto 1.773 1.320-2.382 .000
Graves 10.844 6.499-18.093 .000
Plummer's 5.191 3.261-8.264 .000
SHTN .103 .054-.197 .000
Benign tumour .216 .175-.266 .000
PTMC 1.452 1.098-1.922 .009
aBenign thyroid disease; bPapillary thyroid microcarcinoma; cOdds ratio;
dConfidence interval; eStatistical significance; fMultinodular goitre; gSolitary
hyperfunctional thyroid nodule.
Table 4 Multivariate logistic regression of each type of
BTDa in relation to PTMCb adjusted for age, sex and
extent of operation
Variable ORc 95% CId pe
MNGf 1.004 .961-1.085 .974
Hashimoto 1.606 1.200-2.148 .001
Graves .724 .532-.986 .041
Plummer's .704 .487-1.019 .063
SHTNg .402 .199-.813 .011
Benign tumour 1.176 .915-1.511 .205
aBenign thyroid disease; bPapillary thyroid microcarcinoma; cOdds ratio;
dConfidence interval; eStatistical significance; fMultinodular goitre; gSolitary
hyperfunctional thyroid nodule.
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performed, except for MNG. Furthermore, the extent of
surgery was highly statistically significantly related to the
presence of PTMC, proving that the extent of surgery is
an independent positive predictor of PTMC (OR 1.45,
95% CI 1.10-1.92, p < 0.009). Table 4 shows the results of
the third MLR model we performed where we tested each
type of BTD and its relation to PTMC, adjusted for sex,
age and extent of surgery. We can clearly observe that an
independent positive predictor for PTMC in relation to
the type of BTD, is Hashimoto thyroiditis (OR 1.61, 95%
CI 1.20-2.15, p = 0.001), whereas Graves disease (OR 0.72,
95% CI 0.53-0.99, p = 0.041) and SHTN (OR 0.40, 95% CI
0.20-0.81, p = 0.011) are independent negative predictors
of PTMC. In other words, we can expect a higher inci-
dence of PTMC in patients with Hashimoto thyroiditis,
while in patients with Graves’s disease and a SHTN we
can expect a lower incidence of PTMC. The results for
Plummer's disease came close to statistical significance
(OR 0.70, 95% CI 0.49-1.02, p = 0.06) following a similar
pattern as for other hyperthyroid diseases.
Discussion
The prevalence of PTMC in autopsy series ranges from
1.7 to 35.6% [10-13]. In clinical series, the incidence of
PTMC in patients operated for BTD is much lower, and
ranges from 3% to 17% [14-16]. Our present study re-
vealed a higher incidence of PTMC compared to our
previous study of PTMC incidence [17]. First of all, a
possible reason for this finding is related to a more ra-
dical approach to BTD surgery we advocate now, whichwas not the case at the time of our previous study. Com-
pared to the time of our previous study, now BTD pa-
tients undergo TT twice as often. This has proved to be
highly statistically significant in another of our studies.
In that study, we compared two periods, a decade apart,
and found that in the first period, only a third of BTD
patients had a TT; while in the second period nearly
80% of BTD patients, had a TT [18]. Secondly, such an
increase of PTMC could be the result of the increasing
number of routine histological sections performed on
the thyroid gland over the past decade; thus leading to an
increased detection of smaller PTMC, that would not have
been revealed in past histopathological examinations. Even
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[19]; we do not believe that this could fully explain the
noted increase of incidence, especially since our pathohis-
tological protocols have not changed much in the past
decade.
In our study we did not find sex to be an independent
predictor for PTMC, although there was a 1% higher in-
cidence among male patients (17.2% vs. 16.2%). Even
though the male sex is considered a prognostic factor
and is independently related to the clinical course of
PTMC and even overall survival; it has not been found
to be an independent predictor for PTMC [20]. On the
contrary, gender is a well known risk factor for PTC
[21,22]. These findings imply that PTMC should be
treated as a different entity compared to PTC after sur-
gery. In this line, in our study there were approximately
six times more females with PTMC than males, but
there were also nearly six times more female patients.
Noguchi et al. find a even higher female-to-male PTMC
ratio in their study (9:1) [8]. Roti et al. agree that sex is
not a independent predictor for PTMC and explain the
higher incidence of PTMC in women being the result of a
higher incidence of BTD in women; thus women are more
frequently exposed to diagnostic and therapeutic proce-
dures [23]. Furthermore, autopsy studies decades apart
show that gender is not a risk factor for PTMC [11,12].
Similar to our findings for sex, we did not find age to
be a independent predictor for PTMC or to be related to
PTMC. Again we find evidence that PTMC shows dif-
ferent clinical characteristics compared to PTC. We did
find a generally higher incidence of PTMC in older age
groups with the peak being in the 51-60 age group, but
without statistical significance. More than half of PTMC
was in the age range 41-60, but this age range also com-
prised nearly half of all patients included in the study.
Some authors find that age is related to PTMC as a
prognostic factor, while others don't, but it is not consi-
dered a independent predictor [8,24,25]. Even though
certain authors consider age as an independent predictor
of PTMC, for patients older than 45 years, autopsy stud-
ies do not show such a pattern [13,26].
The incidence of PTMC in MNG is generally high,
and based on previous studies, varies significantly ran-
ging from 7 to 17% [17,27-31]. Even though our previous
study found that the highest incidence of PTMC was in
the MNG group (13.4%), and this study showed an even
higher incidence (16.4%), we did not find it to be statisti-
cally significant [17]. There is a general consensus that a
higher rate of TC is found in goitres with a solitary no-
dule than in MNG, but numerous studies have demon-
strated that in fact there is no difference in the incidence
of TC in these two entities [32]. Our study demonstrated
that this can be applied to PTMC, also. In the group
with benign tumours there was also a high incidence ofPTMC, but it did not differ much from the MNG group
and was in fact lower (16.2% vs. 16.4%). This coincides
with the results of the study of Mihailescu and Schneider,
who find that the likelihood of TC is increased if more
than one nodule is present in patients at high risk of TC
[33]. On the contrary, Barroeta et al. find that TC risk de-
creases with three or more nodules [34]. Taking this into
account, and the results of our study where we did not
find a statistical association between PTMC and MNG or
benign tumours, we can conclude that these BTDs cannot
be considered as independent predictors for PTMC.
Our study showed that Hashimoto disease is an inde-
pendent positive predictor for PTMC. Previous studies
suggest that Hashimoto thyroiditis patients have a higher
risk of TC, mainly as a result of chronic inflammation
[35-37]. Likewise, Kim et al. find that it is significantly
related to PTMC and its clinical course [38]. Fiore et al.
in their study of roughly 10,000 patients demonstrated
that TSH levels are higher in patients with PTC and that
the prevalence increases with TSH, being the highest in
patients with serum TSH in the upper limit of the nor-
mal range [39]. During the natural course of Hashimoto
thyroiditis disease, we can reasonably presume that these
patients were exposed to higher levels of TSH, in a cer-
tain time frame, and that that this could have in fact be
the reason for a higher incidence of PTMC among these
patients. Kim and Park give further evidence for this hy-
pothesis in their study that found a similar correlation
between the sole level of TSH and TC; even in patients
without thyroid autoimmune diseases [40]. In contrast,
Sugitani et al. do not find a positive correlation between
TSH and PTMC [41]. Probably, the most likely cause for
a higher incidence of PTMC in Hashimoto thyroiditis
disease is dual; as the result of chronic inflammation and
the prolonged influence of a higher level of TSH. We
should also consider that patients with high TSH levels,
who go untreated for a long period of time, will develop
thyroid enlargement and will eventually undergo surgery
because of mechanical compression and thus the per-
centage of such patients would be higher and could
artificially increase the rate of incidentally discovered
PTMC.
On the contrary, long-term suppressed levels of TSH,
as in patients with hyperthyroidism, would imply a lower
incidence of TC. This proved to be true in our study
where hyperthyroid diseases were found to be indepen-
dent negative predictors of PTMC. There was a highly
significant reduced risk of PTMC in patients with a
SHTN or Graves disease (OR 0.40 and 0.72, respec-
tively), and close to significant (p = 0.063) reduced risk
(OR 0.70) in patients with Plummer's disease. It seems
that a low level of TSH, surpasses the effect of chronic
inflammation, as in Graves diseases. Chigot et al. in their
study of 861 patients with hyperthyroidism conclude
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development of TC [42]. A 3% incidence of TC has been
reported historically for Plummer's disease; but in a
more recent ten-year study comprising 2500 patients an
incidence of 18% was found, suggesting that this rate has
been underestimated [43]. Our study, with nearly the
same number of patients, found a lower incidence
(13.7%) for Plummer's disease, but a higher incidence for
SHTN (4.5% vs. 6.6%).
In our present study, the incidence of PTMC in BTD
is statistically connected with the extent of surgery and
we found a threefold increase in the incidence of PTMC
in the TT group compared to the HT group. According
to our study, there is a higher risk for finding PTMC in
patients that undergo TT (OR 1.45). The extent of sur-
gery for BTD is still questionable, and varies from TT, to
HT. [44,45] At our Centre we advocate TT, whenever
possible, for patients with BTD, except for SHTNs and
unilateral benign tumours, since it provides better con-
trol of the disease; and as a method of secondary pre-
vention of reoperations that carry a much higher risk of
complications. Feroci F et al. in their meta-analysis show
that TT offers a better chance of cure of hyperthyroi-
dism than HT and can be accomplished safely with only
a small increase in temporary and permanent hypopara-
thyroidism [46]. Yoldas et al. in their study of 748 pa-
tients with MNG, find a high recurrence rate of 29%
among their patients who underwent HT; and therefore
recommend that HT should be discontinued and TT
should be preferred, while keeping in mind the proba-
bility of a higher risk of hypoparathyroidism [47]. To re-
duce the risk of postoperative permanent hypocalcaemia
we perform HT, such as the Dunhill operation, as a co-
erced surgical procedure, for those patients in which we
did not reliably identify the vascularisation of the para-
thyroid glands on the first side of the operated thyroid
gland. Furthermore, according to our investigation, we
agree with Pisello et al. that TT for patients with BTD is
recommended, in the light of a not so insignificant inci-
dence of PTMC in BTD [48]. Patients with incidental
PTMC that underwent TT for BTD are easier to follow
up, since we can then use thyroglobulin and thyroglobu-
lin antibodies as tumour markers. Moreover, it is easier
to adjust the right dose of thyroid hormone replacement
therapy for patients with BTD with or without PTMC
that underwent TT. Thus these patients require less fre-
quent controls. Finally, mortality, although low, has been
reported for PTMC [49]. Naturally, this approach can
only be utilized in high-volume endocrine surgery units,
where thyroid surgery can be performed safely with min-
imal morbidity. In such an environment the extent of
surgery has no impairment on the quality of life of these
patients; regardless of the extent of surgery [50]. It is im-
portant to note that the indications for surgery of thesepatients was the patients' BTD, and not PTMC. We
agree with Ito et al. that most low-risk PTMC lacking
aggressive features are harmless, and immediate surgery
for all of them is definitely an overtreatment [25].
Thyroid nodules are a very common clinical finding,
with an estimated prevalence, on the basis of palpation
of 3-7%, and on the basis of ultrasound examination of
20-76% [51]. If age and results of autopsy studies are
also added in to the equation, it can be said that 50% of
60-year-old persons have thyroid nodules [52]. Acknow-
ledging this fact, the clinician finds himself suddenly in a
most awkward predicament. Having detected such a vast
number of patients with thyroid lesions, we are in a
quandary as to what to do with them. This manuscript
was born out of the necessity to find additional criteria
that can be implemented in everyday clinical practice
and that would help us in providing optimal treatment
for such a large number of patients. The first clinical di-
lemma that arises is how to select, from such a vast
number of patients with thyroid lesions, patients that re-
quire surgery and secondly, what is the individual appro-
priate extent of surgery. Fortunately, these are usually
benign lesions, but nonetheless we have to evaluate
which nodules are suspicious of malignancy. Taking into
account that the results of FNAB are not always reliable,
especially in patients with MNG with lots of nodules
and in patients with nodules smaller than 10mm, it is
particularly difficult to establish a sound diagnosis for
small non-palpable nodules that have been verified by
ultrasound only [53,54]. It is important to note that
non-palpable nodules have the same potential for TC as
palpable nodules of the same size [55]. Furthermore, the
risk of TC is nearly the same in incidentally discovered
nodules smaller than 10mm as it is in clinically evident
nodules greater than 10mm [56]. Finally, intraoperative
macroscopic identification of PTMC is not always pos-
sible considering its size; and especially since many
endocrine surgery units have stopped routinely using
frozen section biopsy, which is considered costly and un-
necessary [57].
In this study we determined the incidence of PTMC in
BTD and identified potential independent predictors for
PTMC. There have not been many studies that examined
independent predictors and the incidence of PTMC in
BTD with as many patients as in our study. Naturally, it
would be useful if this study could be repeated on a higher
number of patients, and preferably as a multicentric study
that would include patients from multiple high volume
endocrine surgery units. Furthermore, additional inde-
pendent predictors for PTMC could be identified; which
is the aim of our other ongoing study. Recognizing poten-
tial independent predictors for PTMC would help us in
selecting patients for operative treatment and choosing
the optimal extent of surgery for their disease.
Slijepcevic et al. BMC Cancer  (2015) 15:330 Page 7 of 8Conclusion
Sex and age are not independent predictors for PTMC. In-
dependent positive predictors for PTMC are Hashimoto
thyroiditis and a greater extent of surgery. Independent
negative predictors for PTMC are a SHTN and Graves
disease.
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